Upfront therapy of acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Upfront therapy of acute myeloid leukemia.

Upfront therapy of acute myeloid leukemia.

http://www.wikidata.org/entity/Q37897183

about

A core-shell albumin copolymer nanotransporter for high capacity loading and two-step release of doxorubicin with enhanced anti-leukemia activity.

P2860

Q46216740-2CB562EE-4B23-43B2-A6C2-59C0BF19BC8B

P2860

Upfront therapy of acute myeloid leukemia.

http://www.wikidata.org/entity/Q37897183

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Upfront therapy of acute myeloid leukemia.

@en

Upfront therapy of acute myeloid leukemia.

@nl

type

label

Upfront therapy of acute myeloid leukemia.

@en

Upfront therapy of acute myeloid leukemia.

@nl

prefLabel

Upfront therapy of acute myeloid leukemia.

@en

Upfront therapy of acute myeloid leukemia.

@nl

P1433

Q37897183-ED3956C4-6C08-4F4C-8291-5820CDD9B350

P1476

Q37897183-FB529165-7A8D-4305-87C8-25BFD170A16F

P2093

Q37897183-39CA2680-87A0-4C1A-81E7-1E3DE4FF198C

Q37897183-9DFC4F54-0050-4166-82DD-66A7D2F6ACF3

Q37897183-DB3B3BBE-B3A1-41E4-A456-8733C61FF79A

P2860

Q37897183-056683CD-4C95-42F3-9E70-096C6CC69EDD

Q37897183-0E8A6CB5-4C36-4FD8-8526-A1D9AEF909F3

Q37897183-10C60E72-7A3D-4EAC-B12A-8C72933CC9B0

Q37897183-196391EC-A1BC-4E4C-968B-613DBC769B56

Q37897183-1F30944B-A5C0-4945-A102-2992F1E26749

Q37897183-20BED38F-C0ED-422D-88B3-A6BB3F6BBC2A

Q37897183-24410515-3AD2-4DBF-8A9C-184C072D1DAB

Q37897183-262EE27F-3D6F-4BE8-8136-99366BA4C227

Q37897183-2DEDDF8D-2406-466A-8720-75BD2B7C6331

Q37897183-364F86E7-CB28-4A9F-828A-BFDA01B04406

P2888

Q37897183-0D12BA5D-C0D3-445A-9FAC-5C5B1A114124

P304

Q37897183-50FEABDA-FFC3-442C-9196-1C784D122722

P31

Q37897183-F4F4B340-5211-4A78-943B-C8FDE2BB5013

P356

Q37897183-E7946981-948D-48B9-9BB9-990CD1549D91

P433

Q37897183-48D72A82-8BAF-40C0-A7B8-A20E6B451684

P478

Q37897183-74ADF792-1456-451C-A512-7CB2F64C14D2

P50

Q37897183-2FF8FCCD-103C-4DE8-B383-49BC5942F59D

P577

Q37897183-99D168E3-58CC-4F4F-AE67-3E44A58AAAE4

P698

Q37897183-D19FC092-BC81-46BC-B7C2-74C2AC64E861

P356

S11912-011-0184-X

P1433

Current Oncology Reports

P1476

Upfront therapy of acute myeloid leukemia

@en

P2093

Bhavana Bhatnagar

http://www.w3.org/2001/XMLSchema#string

Ivana Gojo

http://www.w3.org/2001/XMLSchema#string

Maria R Baer

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

P2888

s11912-011-0184-x

P304

361-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-011-0184-X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Jenna Vanliere Canzoniero

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21725902

http://www.w3.org/2001/XMLSchema#string